Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.

ABSTRACT:

SUBMITTER: Derman BA 

PROVIDER: S-EPMC7873068 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature